Cargando…

Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial

Objective To investigate whether symptomatic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is non-inferior to antibiotics in the treatment of uncomplicated lower urinary tract infection (UTI) in women, thus offering an opportunity to reduce antibiotic use in ambulatory care. Design R...

Descripción completa

Detalles Bibliográficos
Autores principales: Kronenberg, Andreas, Bütikofer, Lukas, Odutayo, Ayodele, Mühlemann, Kathrin, da Costa, Bruno R, Battaglia, Markus, Meli, Damian N, Frey, Peter, Limacher, Andreas, Reichenbach, Stephan, Jüni, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672899/
https://www.ncbi.nlm.nih.gov/pubmed/29113968
http://dx.doi.org/10.1136/bmj.j4784
_version_ 1783276521652224000
author Kronenberg, Andreas
Bütikofer, Lukas
Odutayo, Ayodele
Mühlemann, Kathrin
da Costa, Bruno R
Battaglia, Markus
Meli, Damian N
Frey, Peter
Limacher, Andreas
Reichenbach, Stephan
Jüni, Peter
author_facet Kronenberg, Andreas
Bütikofer, Lukas
Odutayo, Ayodele
Mühlemann, Kathrin
da Costa, Bruno R
Battaglia, Markus
Meli, Damian N
Frey, Peter
Limacher, Andreas
Reichenbach, Stephan
Jüni, Peter
author_sort Kronenberg, Andreas
collection PubMed
description Objective To investigate whether symptomatic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is non-inferior to antibiotics in the treatment of uncomplicated lower urinary tract infection (UTI) in women, thus offering an opportunity to reduce antibiotic use in ambulatory care. Design Randomised, double blind, non-inferiority trial. Setting 17 general practices in Switzerland. Participants 253 women with uncomplicated lower UTI were randomly assigned 1:1 to symptomatic treatment with the NSAID diclofenac (n=133) or antibiotic treatment with norfloxacin (n=120). The randomisation sequence was computer generated, stratified by practice, blocked, and concealed using sealed, sequentially numbered drug containers. Main outcome measures The primary outcome was resolution of symptoms at day 3 (72 hours after randomisation and 12 hours after intake of the last study drug). The prespecified principal secondary outcome was the use of any antibiotic (including norfloxacin and fosfomycin as trial drugs) up to day 30. Analysis was by intention to treat. Results 72/133 (54%) women assigned to diclofenac and 96/120 (80%) assigned to norfloxacin experienced symptom resolution at day 3 (risk difference 27%, 95% confidence interval 15% to 38%, P=0.98 for non-inferiority, P<0.001 for superiority). The median time until resolution of symptoms was four days in the diclofenac group and two days in the norfloxacin group. A total of 82 (62%) women in the diclofenac group and 118 (98%) in the norfloxacin group used antibiotics up to day 30 (risk difference 37%, 28% to 46%, P<0.001 for superiority). Six women in the diclofenac group (5%) but none in the norfloxacin group received a clinical diagnosis of pyelonephritis (P=0.03). Conclusion Diclofenac is inferior to norfloxacin for symptom relief of UTI and is likely to be associated with an increased risk of pyelonephritis, even though it reduces antibiotic use in women with uncomplicated lower UTI. Trial registration ClinicalTrials.gov NCT01039545.
format Online
Article
Text
id pubmed-5672899
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-56728992017-11-16 Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial Kronenberg, Andreas Bütikofer, Lukas Odutayo, Ayodele Mühlemann, Kathrin da Costa, Bruno R Battaglia, Markus Meli, Damian N Frey, Peter Limacher, Andreas Reichenbach, Stephan Jüni, Peter BMJ Research Objective To investigate whether symptomatic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is non-inferior to antibiotics in the treatment of uncomplicated lower urinary tract infection (UTI) in women, thus offering an opportunity to reduce antibiotic use in ambulatory care. Design Randomised, double blind, non-inferiority trial. Setting 17 general practices in Switzerland. Participants 253 women with uncomplicated lower UTI were randomly assigned 1:1 to symptomatic treatment with the NSAID diclofenac (n=133) or antibiotic treatment with norfloxacin (n=120). The randomisation sequence was computer generated, stratified by practice, blocked, and concealed using sealed, sequentially numbered drug containers. Main outcome measures The primary outcome was resolution of symptoms at day 3 (72 hours after randomisation and 12 hours after intake of the last study drug). The prespecified principal secondary outcome was the use of any antibiotic (including norfloxacin and fosfomycin as trial drugs) up to day 30. Analysis was by intention to treat. Results 72/133 (54%) women assigned to diclofenac and 96/120 (80%) assigned to norfloxacin experienced symptom resolution at day 3 (risk difference 27%, 95% confidence interval 15% to 38%, P=0.98 for non-inferiority, P<0.001 for superiority). The median time until resolution of symptoms was four days in the diclofenac group and two days in the norfloxacin group. A total of 82 (62%) women in the diclofenac group and 118 (98%) in the norfloxacin group used antibiotics up to day 30 (risk difference 37%, 28% to 46%, P<0.001 for superiority). Six women in the diclofenac group (5%) but none in the norfloxacin group received a clinical diagnosis of pyelonephritis (P=0.03). Conclusion Diclofenac is inferior to norfloxacin for symptom relief of UTI and is likely to be associated with an increased risk of pyelonephritis, even though it reduces antibiotic use in women with uncomplicated lower UTI. Trial registration ClinicalTrials.gov NCT01039545. BMJ Publishing Group Ltd. 2017-11-08 /pmc/articles/PMC5672899/ /pubmed/29113968 http://dx.doi.org/10.1136/bmj.j4784 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Kronenberg, Andreas
Bütikofer, Lukas
Odutayo, Ayodele
Mühlemann, Kathrin
da Costa, Bruno R
Battaglia, Markus
Meli, Damian N
Frey, Peter
Limacher, Andreas
Reichenbach, Stephan
Jüni, Peter
Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial
title Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial
title_full Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial
title_fullStr Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial
title_full_unstemmed Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial
title_short Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial
title_sort symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672899/
https://www.ncbi.nlm.nih.gov/pubmed/29113968
http://dx.doi.org/10.1136/bmj.j4784
work_keys_str_mv AT kronenbergandreas symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT butikoferlukas symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT odutayoayodele symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT muhlemannkathrin symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT dacostabrunor symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT battagliamarkus symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT melidamiann symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT freypeter symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT limacherandreas symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT reichenbachstephan symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial
AT junipeter symptomatictreatmentofuncomplicatedlowerurinarytractinfectionsintheambulatorysettingrandomiseddoubleblindtrial